KSKah Teong Soh

Kah Teong Soh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kah Teong Soh has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Paul K. Wallace

    Department of Flow and Image Cytometry Roswell Park Comprehensive Cancer Center Buffalo New York

    3 shared publications
  • Jens Hillengass

    Department of Medicine Roswell Park Comprehensive Cancer Center Buffalo New York

    1 shared publication
  • Joseph D. Tario

    Department of Flow and Image Cytometry Roswell Park Comprehensive Cancer Center Buffalo New York

    1 shared publication
  • Joseph D. Tario

    Flow Cytometry Laboratory (Clinical), Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA

    1 shared publication
  • Paul K. Wallace

    Department of Flow and Image Cytometry, Roswell Park Cancer Institute, Buffalo, New York

    1 shared publication
  • Philip L. McCarthy

    Department of Medicine Roswell Park Comprehensive Cancer Center Buffalo New York

    1 shared publication

Latest Publications

  • Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease

    by Kah Teong Soh, Joseph D. Tario, Theresa E Hahn, Jens Hillengass, Philip L. McCarthy, Paul K. Wallace

    Background: Recent advances in therapeutic interventions have dramatically improved complete response rates in patients with multiple myeloma (MM). The ability to identify residual myeloma cells (e.g., measurable residual disease [MRD]) can provide valuable information pertaining to patient's depth of response to therapy and risk of relapse. Multiparametric flow cytometry is an excellent technique to monitor MRD and has been demonstrated to correlate with patient outcome post‐treatment. To achieve the high sensitivity (one abnormal cell in 105–106 cells) required for MRD evaluation, millions of cells have to be acquired and conventional immunophenotyping protocols are unable to attain these numbers, indicating the needs for alternative flow cytometric staining procedures. A bulk, “Pre‐lysis” method is the consensus approach for staining large number of cells, requires two red blood cell lysis steps, and can adversely affect epitope density. In this study, we tested the “Pooled‐tube” and “Dextran Sedimentation” staining procedures and correlated them with the “Pre‐lysis” method as potential alternative approaches.Methods: A total of 22 bone marrow aspirates from patients with plasma cell (PC) dyscrasia were processed in parallel using the “Pre‐lysis,” “Pooled‐tube,” and “Dextran Sedimentation” techniques. Stain indices were calculated and compared to assess their impacts on staining performance for each antibody used in the consensus panel. The recovery of normal and abnormal PCs, mast cells, and B cell precursors was enumerated and compared after their counts were normalized using fluorescent beads. The limit of blank, limit of detection, and lower limit of quantification were established using serial dilution experiments.Results: The staining performances of CD19 PECy7, CD27 BV510, CD81 APCH7, and CD138 BV421 were improved using the “Pooled‐tube” method when compared to “Pre‐lysis.” “Pre‐lysis” was better at resolving CD56 using clone C5.9 but our results demonstrated similar improvement can also be achieved by “Pooled‐tube” when alternative CD56 PE clones were used. “Dextran sedimentation” yielded similar staining results when compared to “Pre‐lysis” for all the markers analyzed. The “Pooled‐tube” method, when normalized to “Pre‐lysis,” recovered higher numbers of total PCs (1.2 ± 0.2 times higher; p = .049), normal PCs (1.4 ± 0.26; p = .007), mast cells (1.46 ± 0.27; p = .003), and B cell precursors (1.42 ± 0.3; p = .011), but not abnormal PCs (1.09 ± 0.2; p = .352). There was no evidence that the recovery of cells was different between “Pre‐lysis” versus “Dextran Sedimentation.” All three flow cytometric assays achieved a minimum sensitivity of 10−5 and approached that of 10−6 for detecting rare events.Conclusion: Both “Pooled‐tube” and “Dextran Sedimentation” staining procedures were comparable to the “Pre‐lysis” method and are suitable high sensitivity flow cytometric approaches that can be used to process bone marrow samples for MM MRD testing.


  • Open Access

    Monitoring of Measurable Residual Disease in Multiple Myeloma by Multiparametric Flow Cytometry

    by Kah Teong Soh, Paul K. Wallace

    Recent interest in high‐sensitivity multiple myeloma (MM) measurable residual disease (MRD) testing is a direct consequence of the high‐quality responses achieved using novel therapeutic agents and better treatment strategies. Traditional diagnostic measures such as immunohistochemistry and morphology have detection sensitivities of only 10−2 to 10−3, which do not reliably predict progression‐free survival (PFS) or overall survival (OS) after these treatments. Contemporary monitoring of MM MRD has switched to more sensitive platforms such as allele‐specific oligonucleotide quantitative polymerase chain reaction (ASO‐qPCR), next‐generation sequencing (NGS), and multiparametric flow cytometry (MFC). Though both ASO‐qPCR and NGS have excellent detection sensitivities (10−5 to 10−6), both technologies have lower applicability when compared to MFC. Conventional MFC can easily reach a detection sensitivity of 10−4 and when optimized can achieve a sensitivity of 10−5 to 10−6. Current consensus guidelines require a minimum of 2 million and recommend 5 million events be acquired to reach a minimum sensitivity of 10−5. As conventional immunophenotyping protocols are unable to attain these numbers, alternative MFC staining procedures are required. This article describes two high‐sensitivity MFC approaches that can be used for MM MRD testing. © 2019 by John Wiley & Sons, Inc.


  • RNA Flow Cytometry Using the Branched DNA Technique

    by Kah Teong Soh, Paul K. Wallace

    The systematic modulation of mRNA and proteins governs the complicated and intermingled biological functions of our cells. Traditionally, transcriptomic technologies such as DNA microarray and RNA-Seq have been used to identify, characterize, and profile gene expression data. These are, however, considered bulk methods as they are unable to measure gene expression at the single-cell level, unless the cells are pre-sorted. Branched DNA is a flow cytometry-based detection platform that has been developed recently to measure mRNA at the single-cell level. Originally adapted from microscopy, the current system has been modified to achieve compatibility with the detection of surface and intracellular antigens using monoclonal antibodies conjugated to fluorochromes, thus permitting simultaneous detection of mRNAs and proteins. The Branched DNA method offers a variety of advantages when compared to traditional or standard methods used for the quantification of mRNA, such as (a) the detection of specific mRNA on a per cell basis, (b) an alternate detection tool when the measurement of a protein is technically infeasible (i.e., no quality antibody exists) or the epitope is not assessable, and (c) correlate the analysis of mRNA with protein. Compared to earlier attempts at measuring nucleic acid by flow cytometry, the hybridization temperature applied in the Branched DNA assay is much lower, thus preserving the integrity of cellular structures for further characterization. It also has greatly increased specificity and sensitivity. Here, we provide detailed instruction for performing the Branched DNA method using it in a model system to correlate the expression of CD8 mRNA and CD8 protein by flow cytometry.